Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 3/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.42 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109055 | 0.84 | ADRB3 (0.65) | ADRB3ADRB2ADRB1 | |
| SCHEMBL5436707 | 0.80 | ADRB2 (0.63) | ADRB3ADRB2ADRB1 | |
| SCHEMBL175681 | 0.80 | PPARD (0.50) | MEN1KMT2A | |
| SCHEMBL8757447 | 0.75 | ADRB2 (0.67) | ADRB3ADRB2ADRB1CYP1A2 | |
| SCHEMBL14106867 | 0.75 | ADRB3 (0.54) | ADRB3ADRB2ADRB1MEN1KMT2A | |
| SCHEMBL15387243 | 0.72 | HSD17B10 (0.49) | ERCC1ERCC4 | |
| SCHEMBL11757626 | 0.72 | ADRB3 (0.71) | ADRB3ADRB2ADRB1MEN1KMT2A | |
| SCHEMBL4019934 | 0.71 | PTPN7 (0.59) | MEN1KMT2A | |
| SCHEMBL4483490 | 0.70 | ERCC1 (0.37) | ADRB3ADRB2ADRB1ERCC1ERCC4 | |
| SCHEMBL11753802 | 0.70 | ADRB3 (0.68) | ADRB3ADRB2ADRB1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | SNOW ALAN D | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197965-A1 | Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs; Alzheimer's disease; diabetes; A beta amyloidosis | IAPP, APP, SNCA | ADRB3 138/4885ADRB2 62/4885ADRB1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.